title: Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.
abstract: A prospective, randomised, multicentre, single-blind phase 3 study was performed to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN "adults" (five consecutive lots) in comparison to another licensed TBE vaccine (Encepur), with polygeline) (two lots) in healthy volunteers (n=3966) aged 16-65 years. The safety of the third vaccination with FSME-IMMUN "adults" (6 months after the first vaccination) was investigated in a follow-up study on the same population (n=3705) and TBE antibody titres were analysed pre- and post-vaccination in a subgroup of volunteers (n=564). Following the first vaccination, the overall incidence of fever (> or =38.0 degrees C) was 0.8% in the FSME-IMMUN "adults" study group and 5.6% in the comparator study group; fever was mainly mild. The fever rate after the second vaccination was 0.6% and 0.5% in the two study groups, respectively. Local and systemic reactions after the first vaccination occurred with a lower frequency in the FSME-IMMUN "adults" study group than in the comparator group. Upon analysing the tolerability of the third vaccination with FSME-IMMUN "adults", similar results were determined in both study groups of volunteers previously vaccinated with FSME-IMMUN "adults" or with the comparator vaccine. The immunogenicity results demonstrated similar seroconversion rates (as determined by ELISA or neutralization test) before and after the third vaccination in the FSME-IMMUN "adults" group and in the comparator group respectively. The results of both studies demonstrate that: (1) FSME-IMMUN "adults" is safe and highly immunogenic, (2) all five production lots of FSME-IMMUN "adults" were consistent with respect to a low rate of adverse events, (3) FSME-IMMUN "adults" induces considerably lower adverse reaction rates than the comparator vaccine after the first vaccination, and (4) two vaccinations with the comparator vaccine can be successfully followed by a third vaccination with FSME-IMMUN "adults".
authors.affiliation: Baxter BioScience, Global Clinical R&D, Industriestr. 67, A-1221Vienna, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Loew-Baselli
authors.forename: R
authors.initials: R
authors.lastname: Konior
authors.forename: B G
authors.initials: BG
authors.lastname: Pavlova
authors.forename: S
authors.initials: S
authors.lastname: Fritsch
authors.forename: E
authors.initials: E
authors.lastname: Poellabauer
authors.forename: F
authors.initials: F
authors.lastname: Maritsch
authors.forename: P
authors.initials: P
authors.lastname: Harmacek
authors.forename: M
authors.initials: M
authors.lastname: Krammer
authors.forename: P N
authors.initials: PN
authors.lastname: Barrett
authors.forename: H J
authors.initials: HJ
authors.lastname: Ehrlich
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D014611:Vaccination; D014765:Viral Vaccines / Q000009:adverse effects* / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D014765:Viral Vaccines